Ortega-Paz L, Capodanno D, Montalescot G, Angiolillo DJ. Coronavirus disease 2019-associated thrombosis and coagulopathy: review of the pathophysiological characteristics and implications for antithrombotic management. J Am Heart Assoc. 2021;10(3):e019650.

CAS  PubMed  PubMed Central  Article  Google Scholar 

WHO Coronavirus (COVID-19) Dashboard: weekly epidemiological updates until February 22, 2022. https://covid19.who.int/.

Al-Samkari H, Gupta S, Leaf RK, Wang W, Rosovsky RP, Brenner SK, et al. Thrombosis, bleeding, and the observational effect of early therapeutic anticoagulation on survival in critically ill patients with COVID-19. Ann Intern Med. 2021;174(5):622–32.

PubMed  Article  Google Scholar 

Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary vascular Endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020;383(2):120–8.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Al-Samkari H, Karp Leaf RS, Dzik WH, Carlson JCT, Fogerty AE, Waheed A, et al. COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood. 2020;136(4):489–500.

CAS  PubMed  Article  Google Scholar 

Poor HD. Pulmonary thrombosis and thromboembolism in COVID-19. Chest. 2021;160(4):1471–80.

CAS  PubMed  Article  Google Scholar 

Giossi R, Menichelli D, Pani A, Tratta E, Romandini A, Roncato R, et al. A systematic review and a Meta-analysis comparing prophylactic and therapeutic low molecular weight heparins for mortality reduction in 32,688 COVID-19 patients. Front Pharmacol. 2021;12:698008.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Ionescu F, Jaiyesimi I, Petrescu I, Lawler PR, Castillo E, Munoz-Maldonado Y, et al. Association of anticoagulation dose and survival in hospitalized COVID-19 patients: a retrospective propensity score-weighted analysis. Eur J Haematol. 2021;106(2):165–74.

CAS  PubMed  Article  Google Scholar 

Rosenberg RD. Actions and interactions of antithrombin and heparin. N Engl J Med. 1975;292(3):146–51.

CAS  PubMed  Article  Google Scholar 

Nadkarni GN, Lala A, Bagiella E, Chang HL, Moreno PR, Pujadas E, et al. Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19. J Am Coll Cardiol. 2020;76(16):1815–26.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Perepu US, Chambers I, Wahab A, Ten Eyck P, Wu C, Dayal S, et al. Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: a multi-center, open-label, randomized controlled trial. J Thromb Haemost. 2021;19(9):2225–34.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Goligher EC, Bradbury CA, McVerry BJ, Lawler PR, Berger JS, Gong MN, et al. Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. N Engl J Med. 2021;385(9):777–89.

PubMed  Article  Google Scholar 

Lemos ACB, Do Espírito Santo DA, Salvetti MC, Gilio RN, Agra LB, Pazin-Filho A, et al. Therapeutic versus prophylactic anticoagulation for severe COVID-19: a randomized phase II clinical trial (HESACOVID). Thromb Res. 2020;196:359–66.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Lopes RD, de Barros ESPGM, Furtado RHM, Macedo AVS, Bronhara B, Damiani LP, et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet. 2021;397(10291):2253–63.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.

PubMed  PubMed Central  Article  Google Scholar 

Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.

PubMed  PubMed Central  Article  Google Scholar 

Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle–Ottawa Scale (NOS) for Assessing the Quality of Non-Randomized Studies in Meta-Analysis; 2000.

Google Scholar 

Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation. 2011;123(23):2736–47.

PubMed  Article  Google Scholar 

Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692–4.

CAS  PubMed  Article  Google Scholar 

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.

PubMed  PubMed Central  Article  Google Scholar 

Spyropoulos AC, Goldin M, Giannis D, Diab W, Wang J, Khanijo S, et al. Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for Thromboprophylaxis in high-risk hospitalized patients with COVID-19: the HEP-COVID randomized clinical trial. JAMA Intern Med. 2021;181(12):1612–20.

CAS  PubMed  Article  Google Scholar 

Lawler PR, Goligher EC, Berger JS, Neal MD, McVerry BJ, Nicolau JC, et al. Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. N Engl J Med. 2021;385(9):790–802.

PubMed  Article  Google Scholar 

Marcos-Jubilar M, Carmona-Torre F, Vidal R, Ruiz-Artacho P, Filella D, Carbonell C, et al. Therapeutic versus prophylactic Bemiparin in hospitalized patients with nonsevere COVID-19 pneumonia (BEMICOP study): an open-label, multicenter, randomized, controlled Trial. Thromb Haemost. 2022;122(2):295–9.

PubMed  Article  Google Scholar 

Sholzberg M, Tang GH, Rahhal H, AlHamzah M, Kreuziger LB, Áinle FN, et al. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ. 2021;375:n2400.

PubMed  Article  Google Scholar 

Morici N, Podda G, Birocchi S, Bonacchini L, Merli M, Trezzi M, et al. Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: The X-COVID-19 Randomized Trial. Eur J Clin Investig. 2021;52:e13735.

Google Scholar 

Connors JM, Brooks MM, Sciurba FC, Krishnan JA, Bledsoe JR, Kindzelski A, et al. Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19: the ACTIV-4B randomized clinical trial. JAMA. 2021;326(17):1703–12.

CAS  PubMed  Article  Google Scholar 

Sadeghipour P, Talasaz AH, Rashidi F, Sharif-Kashani B, Beigmohammadi MT, Farrokhpour M, et al. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial. JAMA. 2021;325(16):1620–30.

CAS  PubMed  Article  Google Scholar 

Di Castelnuovo A, Costanzo S, Antinori A, Berselli N, Blandi L, Bonaccio M, et al. Heparin in COVID-19 patients is associated with reduced in-hospital mortality: the multicenter Italian CORIST study. Thromb Haemost. 2021;121(8):1054–65.

PubMed  Article  Google Scholar 

Elmelhat A, Elbourai E, Dewedar H, Elgergawi T, Alkhanbouli M, Ahmed S, et al. Comparison between prophylactic versus therapeutic doses of low-molecular-weight heparin in severely ill coronavirus disease 2019 patients in relation to disease progression and outcome. Dubai Med J. 2020;3(4):162–9.

Article  Google Scholar 

Gonzalez-Porras JR, Belhassen-Garcia M, Lopez-Bernus A, Vaquero-Roncero LM, Rodriguez B, Carbonell C, et al. Low molecular weight heparin is useful in adult COVID-19 inpatients. Experience during the first Spanish wave: observational study. Sao Paulo Med J. 2022;140(1):123–33.

PubMed  Article  Google Scholar 

Hamad MA, Dasuqi SA, Aleem A, Omran RA, AlQahtani RM, Alhammad FA, et al. Assessment of anti-factor Xa activity in critically ill COVID-19 patients receiving three different anticoagulation regimens. SAGE Open Med. 2021;9:20503121211049931.

PubMed  PubMed Central  Article  Google Scholar 

Helms J, Severac F, Merdji H, Schenck M, Clere-Jehl R, Baldacini M, et al. Higher anticoagulation targets and risk of thrombotic events in severe COVID-19 patients: bi-center cohort study. Ann Intensive Care. 2021;11(1):14.

CAS  PubMed  PubMed Central  Article  Google Scholar 

Martinelli I, Ciavarella A, Abbattista M, Aliberti S, De Zan V, Folli C, et al. Increasing dosages of low-molecular-weight heparin in hospitalized patients with Covid-19. Intern Emerg Med. 2021;16(5):1223–9.

PubMed  PubMed Central  Article  Google Scholar 

Battistoni I, Francioni M, Morici N, Rubboli A, Podda GM, Pappalardo A, et al. Pre- and in-hospital anticoagulation therapy in coronavirus disease 2019 patients: a propensity-matched analysis of in-hospital outcomes. J Cardiovasc Med (Hagerstown). 2022;23(4):264–71.

Kaur J, Sule AA, Koehler T, Krishnamoorthy G, DeLongpre J. Anticoagulation management and outcomes in Covid-19 patients:a multi-center retrospective cohort study. Blood. 2020;136:34.

Article  Google Scholar 

Canoglu K, Saylan B. Therapeutic dosing of low-molecular-weight heparin may decrease mortality in patients with severe COVID-19 infection. Ann Saudi Med. 2020;40(6):462–8.

PubMed  PubMed Central  Article  Google Scholar 

Qin W, Dong F, Zhang Z, Hu B, Chen S, Zhu Z, et al. Low molecular weight heparin and 28-day mortality among patients with coronavirus disease 2019: a cohort study in the early epidemic era. Thromb Res. 2021;198:19–22.

CAS  PubMed  Article  Google Scholar 

Matli K, Chamoun N, Fares A, Ziba